BR112021026916A2 - Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina - Google Patents

Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina

Info

Publication number
BR112021026916A2
BR112021026916A2 BR112021026916A BR112021026916A BR112021026916A2 BR 112021026916 A2 BR112021026916 A2 BR 112021026916A2 BR 112021026916 A BR112021026916 A BR 112021026916A BR 112021026916 A BR112021026916 A BR 112021026916A BR 112021026916 A2 BR112021026916 A2 BR 112021026916A2
Authority
BR
Brazil
Prior art keywords
rilpivirine
methods
pediatric patients
treating hiv
pediatric
Prior art date
Application number
BR112021026916A
Other languages
English (en)
Inventor
Herta Crauwels
Simon Vanveggel
VAN EYGEN Veerle
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of BR112021026916A2 publication Critical patent/BR112021026916A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

métodos de tratamento de hiv em pacientes pediátricos com rilpivirina. a divulgação está dirigida ao uso de rilpivirina, ou um seu sal, para tratar a infecção pelo hiv em indivíduos pediátricos.
BR112021026916A 2019-07-03 2020-07-02 Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina BR112021026916A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03
PCT/EP2020/068734 WO2021001508A1 (en) 2019-07-03 2020-07-02 Methods of treating hiv in pediatric patients with rilpivirine

Publications (1)

Publication Number Publication Date
BR112021026916A2 true BR112021026916A2 (pt) 2022-05-10

Family

ID=71579550

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112021026916A BR112021026916A2 (pt) 2019-07-03 2020-07-02 Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina
BR112021026739A BR112021026739A2 (pt) 2019-07-03 2020-07-03 Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112021026739A BR112021026739A2 (pt) 2019-07-03 2020-07-03 Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina

Country Status (13)

Country Link
US (3) US20210000823A1 (pt)
EP (2) EP3993799A1 (pt)
JP (2) JP2022538338A (pt)
KR (2) KR20220028049A (pt)
CN (2) CN114126655A (pt)
AU (2) AU2020300818A1 (pt)
BR (2) BR112021026916A2 (pt)
CA (2) CA3144534A1 (pt)
IL (1) IL289457A (pt)
JO (1) JOP20210347A1 (pt)
MA (2) MA56449A (pt)
MX (2) MX2022000060A (pt)
WO (2) WO2021001508A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI494133B (zh) * 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
PL2640362T5 (pl) * 2010-11-19 2022-05-02 Gilead Sciences, Inc. Kompozycje terapeutyczne zawierające hcl rylpiwiryny i fumaran dizoproksylu tenofowiru
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
JP7287906B2 (ja) * 2017-06-30 2023-06-06 ヴィーブ ヘルスケア カンパニー 組み合わせ並びにその使用及びそれによる治療

Also Published As

Publication number Publication date
US20210000823A1 (en) 2021-01-07
CN114126655A (zh) 2022-03-01
CA3144307A1 (en) 2021-01-07
KR20220028049A (ko) 2022-03-08
MX2021015627A (es) 2022-04-25
MA56449A (fr) 2022-05-11
US20240139186A1 (en) 2024-05-02
KR20220028048A (ko) 2022-03-08
CN114080223A (zh) 2022-02-22
JP2022538449A (ja) 2022-09-02
JP2022538338A (ja) 2022-09-01
WO2021001508A1 (en) 2021-01-07
US20220313693A1 (en) 2022-10-06
IL289457A (en) 2022-02-01
MX2022000060A (es) 2022-04-18
EP3993800A1 (en) 2022-05-11
AU2020300033A1 (en) 2022-02-24
WO2021001568A1 (en) 2021-01-07
EP3993799A1 (en) 2022-05-11
AU2020300818A1 (en) 2022-03-03
CA3144534A1 (en) 2021-01-07
MA56453A (fr) 2022-05-11
JOP20210347A1 (ar) 2023-01-30
BR112021026739A2 (pt) 2022-04-26

Similar Documents

Publication Publication Date Title
BR112017019279A2 (pt) kits e dispositivos descartáveis para redução de oxigênio e métodos de uso dos mesmos
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
CU20160187A7 (es) (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13, 13a-octahidro-2,5-metanopirido[1',2':4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio
BR112019009256A2 (pt) métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
BR112017004524A2 (pt) pirrolopirimidinas para uso na infecção pelo vírus da gripe
EA202191133A1 (ru) Сигнатуры интерферона типа i и способы их применения
BR112019000201A2 (pt) compostos e seu uso na redução dos níveis de ácido úrico
BR112018069776A2 (pt) tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
EA201990396A1 (ru) Способ регенерации целлюлозных волокон из использованного впитывающего изделия
CL2016002827A1 (es) Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos.
BR112016016880A2 (pt) Combinação para tratar câncer e seu uso, kit, e composição farmacêutica
PH12015501574A1 (en) Diposable diaper
DK64055C (da) Klokke til Behandling af Muskler og andre dybere liggende Væv i det menneskelige eller dyriske Legeme.
BR112021018815A2 (pt) Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
BR102018068947A8 (pt) sistemas de instrumento cirúrgico ortopédico específicos para um lado do corpo e métodos de uso associados
BR112021026916A2 (pt) Métodos de tratamento de hiv em pacientes pediátricos com rilpivirina
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
EA201891922A1 (ru) Лекарственное средство для лечения инфекций на фоне диабетической стопы
CN104434135B (zh) 一种隐藏式一次性安全采血针
BR112019024875A2 (pt) Métodos para o tratamento da ileíte do reservatório crônica
CL2021001172A1 (es) Uso de tivozanib para tratar sujetos con cáncer refractario.